P2Y12 Receptors in Tumorigenesis and Metastasis

Platelets, beyond their role in hemostasis and thrombosis, may sustain tumorigenesis and metastasis. These effects may occur via direct interaction of platelets with cancer and stromal cells and by the release of several platelet products. Platelets and tumor cells release several bioactive molecules among which a great amount of adenosine triphosphate (ATP) and adenosine diphosphate (ADP). ADP is also formed extracellularly from ATP breakdown by the ecto-nucleoside-triphosphate-diphosphohydrolases. Under ATP and ADP stimulation the purinergic P2Y1 receptor (R) initiates platelet activation followed by the ADP-P2Y12R-mediated amplification. P2Y12R stimulation amplifies also platelet response to several platelet agonists and to flow conditions, acting as a key positive feed-forward signal in intensifying platelet responses. P2Y12R represents a potential target for an anticancer therapy due to its involvement in platelet-cancer cell crosstalk. Thus, P2Y12R antagonists, including clopidogrel, ticagrelor, and prasugrel, might represent potential anti-cancer agents, in addition to their role as effective antithrombotic drugs. However, further studies, in experimental animals and patients, are required before the recommendation of the use of P2Y12R antagonists in cancer prevention and progression can be made.

[1]  Hypoxia-induced resistance to cisplatin-mediated apoptosis in osteosarcoma cells is reversed by gambogic acid independently of HIF-1α , 2016, Molecular and Cellular Biochemistry.

[2]  A. Pandey,et al.  Anti-platelet agents augment cisplatin nanoparticle cytotoxicity by enhancing tumor vasculature permeability and drug delivery , 2014, Nanotechnology.

[3]  Q. Dou,et al.  Metal-based proteasomal deubiquitinase inhibitors as potential anticancer agents , 2017, Cancer and Metastasis Reviews.

[4]  A. Algra,et al.  Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials , 2010, The Lancet.

[5]  J. Sévigny,et al.  The E-NTPDase family of ectonucleotidases: Structure function relationships and pathophysiological significance , 2006, Purinergic Signalling.

[6]  K. Huber,et al.  Response variability to P2Y12 receptor inhibitors: expectations and reality. , 2013, JACC. Cardiovascular interventions.

[7]  H. Weir,et al.  The past, present, and future of cancer incidence in the United States: 1975 through 2020 , 2015, Cancer.

[8]  Z. Fan,et al.  Overcoming cisplatin resistance of ovarian cancer cells by targeting HIF-1-regulated cancer metabolism. , 2016, Cancer letters.

[9]  A. Sood,et al.  Role of ADP receptors on platelets in the growth of ovarian cancer. , 2017, Blood.

[10]  J. Baron.  Aspirin and cancer. , 1995, Preventive medicine.

[11]  F. Fagioli,et al.  Non-myeloablative allogeneic hematopoietic stem cell transplants. , 2002, Haematologica.

[12]  W. Gan,et al.  The P2Y12 receptor regulates microglial activation by extracellular nucleotides , 2006, Nature Neuroscience.

[13]  G. Rousseau.  Purinergic Nerves , 1977, The Lancet.

[14]  P. Mannucci,et al.  Identification of a new congenital defect of platelet function characterized by severe impairment of platelet responses to adenosine diphosphate. , 1992, Blood.

[15]  T. Petrova,et al.  Microenvironmental regulation of tumour angiogenesis , 2017, Nature Reviews Cancer.

[16]  S. Israels,et al.  Platelet dense granules: structure, function and implications for haemostasis. , 1999, Thrombosis research.

[17]  R. Schulz,et al.  Adenosine-mediated effects of ticagrelor: evidence and potential clinical relevance. , 2014, Journal of the American College of Cardiology.

[18]  Feng Zhang,et al.  The angiogenic responses induced by release of angiogenic proteins from tumor cell‐activated platelets are regulated by distinct molecular pathways , 2015, IUBMB life.

[19]  David Julius,et al.  Identification of the platelet ADP receptor targeted by antithrombotic drugs , 2001, Nature.

[20]  B. Karlan,et al.  Platelets reduce anoikis and promote metastasis by activating YAP1 signaling , 2017, Nature Communications.

[21]  C. Gachet.  P2Y12 receptors in platelets and other hematopoietic and non-hematopoietic cells , 2012, Purinergic Signalling.

[22]  M. Cattaneo,et al.  The platelet P2 receptors in inflammation , 2015, Hämostaseologie.

[23]  H. Yamanaka,et al.  Multiple P2Y subtypes in spinal microglia are involved in neuropathic pain after peripheral nerve injury , 2012, Glia.

[24]  Patricia D. Christie,et al.  Targeted disruption of cd39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation , 1999, Nature Medicine.

[25]  Sang‐Hyun Lee,et al.  β‐arrestin 2‐dependent activation of ERK1/2 is required for ADP‐induced paxillin phosphorylation at Ser83 and microglia chemotaxis , 2012, Glia.

[26]  M. Lishner,et al.  The Effect of Combined Aspirin and Clopidogrel Treatment on Cancer Incidence. , 2017, The American journal of medicine.

[27]  K. Tanaka,et al.  Effects of 5-(2-chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine hydrochloride (Ticlopidine), a platelet aggregation inhibitor, on blood-borne metastasis. , 1981, Cancer research.

[28]  P. Nurden,et al.  An inherited bleeding disorder linked to a defective interaction between ADP and its receptor on platelets. Its influence on glycoprotein IIb-IIIa complex function. , 1995, The Journal of clinical investigation.

[29]  G. Burnstock,et al.  Purinergic signalling and immune cells , 2014, Purinergic Signalling.

[30]  D. Mikhailidis,et al.  Platelets and ectonucleotidases. , 1994, Platelets.

[31]  C. Holmes,et al.  The effect of P2Y-mediated platelet activation on the release of VEGF and endostatin from platelets , 2010, Platelets.

[32]  S. Kunapuli,et al.  Role of phosphoinositide 3-kinase beta in platelet aggregation and thromboxane A2 generation mediated by Gi signalling pathways. , 2010, The Biochemical journal.

[33]  P. Patrignani,et al.  Platelets as crucial partners for tumor metastasis: from mechanistic aspects to pharmacological targeting , 2017, Cellular and Molecular Life Sciences.

[34]  G. Guidi,et al.  Relationship between pharmacokinetics and pharmacodynamics of clopidogrel in patients undergoing percutaneous coronary intervention: comparison between vasodilator‐stimulated phosphoprotein phosphorylation assay and multiple electrode aggregometry , 2016, Journal of thrombosis and haemostasis : JTH.

[35]  B. Sessle,et al.  Involvement of Microglial P2Y12 Signaling in Tongue Cancer Pain , 2016, Journal of dental research.

[36]  W. Seo,et al.  Suppression of Akt-HIF-1α signaling axis by diacetyl atractylodiol inhibits hypoxia-induced angiogenesis , 2016, BMB reports.

[37]  S. Kunapuli,et al.  The C6‐2B glioma cell P2YAC receptor is pharmacologically and molecularly identical to the platelet P2Y12 receptor , 2001, British journal of pharmacology.

[38]  A. Bengtsson,et al.  P2 receptor mRNA expression profiles in human lymphocytes, monocytes and CD34+ stem and progenitor cells , 2004, BMC Immunology.

[39]  G. FitzGerald,et al.  Historical lessons in translational medicine: cyclooxygenase inhibition and P2Y12 antagonism. , 2013, Circulation research.

[40]  Gianni Tognoni,et al.  Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials , 2012, The Lancet.

[41]  G. Burnstock.  Purinergic Signaling in the Cardiovascular System. , 2017, Circulation research.

[42]  G. Dubyak,et al.  Detection of local ATP release from activated platelets using cell surface-attached firefly luciferase. , 1999, American journal of physiology. Cell physiology.

[43]  Kirsten Bibbins-Domingo,et al.  Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement. , 2016, Annals of internal medicine.

[44]  F. Chisari,et al.  Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B , 2012, Proceedings of the National Academy of Sciences.

[45]  M. Cattaneo.  Bleeding manifestations of congenital and drug-induced defects of the platelet P2Y12 receptor for adenosine diphosphate , 2011, Thrombosis and Haemostasis.

[46]  G. FitzGerald,et al.  Aspirin prevents colorectal cancer metastasis in mice by splitting the crosstalk between platelets and tumor cells , 2016, OncoTarget.

[47]  J. Vermylen,et al.  ATP Augments von Willebrand Factor-dependent Shear-induced Platelet Aggregation through Ca2+-Calmodulin and Myosin Light Chain Kinase Activation* , 2004, Journal of Biological Chemistry.

[48]  Chunfu Wu,et al.  SYP-5, a novel HIF-1 inhibitor, suppresses tumor cells invasion and angiogenesis. , 2016, European journal of pharmacology.

[49]  J. Schneider,et al.  The ADP receptor P2RY12 regulates osteoclast function and pathologic bone remodeling. , 2012, The Journal of clinical investigation.

[50]  Kazuhide Inoue,et al.  P2Y12 receptor‐mediated integrin‐β1 activation regulates microglial process extension induced by ATP , 2010, Glia.

[51]  M. Freund,et al.  Differential Involvement of the P2Y1 and P2Y12 Receptors in Platelet Procoagulant Activity , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[52]  P. Rothwell,et al.  Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials , 2011, The Lancet.

[53]  R. Figueiredo,et al.  Purinergic P2Y12 Receptor Activation in Eosinophils and the Schistosomal Host Response , 2015, PloS one.

[54]  L. Mao,et al.  P2Y12 Promotes Migration of Vascular Smooth Muscle Cells Through Cofilin Dephosphorylation During Atherogenesis , 2017, Arteriosclerosis, thrombosis, and vascular biology.

[55]  Purinergic signalling and cancer , 2013, Purinergic Signalling.

[56]  S. Kunapuli,et al.  Platelet purinergic receptors. , 2003, Current opinion in pharmacology.

[57]  V. Serebruany,et al.  Survival After Solid Cancers in Antithrombotic Trials. , 2015, The American journal of cardiology.

[58]  M. Cattaneo.  New P2Y12 Inhibitors , 2010, Circulation.

[59]  C. Bode,et al.  Clopidogrel affects leukocyte dependent platelet aggregation by P2Y12 expressing leukocytes , 2010, Basic Research in Cardiology.

[60]  A. Zaman,et al.  Cancer Event Rate and Mortality with Thienopyridines: A Systematic Review and Meta-Analysis , 2017, Drug Safety.

[61]  L. B. Drobot,et al.  Differential effects of P2Y1 and P2Y12 nucleotide receptors on ERK1/ERK2 and phosphatidylinositol 3‐kinase signalling and cell proliferation in serum‐deprived and nonstarved glioma C6 cells , 2004, British journal of pharmacology.

[62]  M. Beznák.  Cardiac Output in Rats During the Development of Cardiac Hypertrophy , 1958, Circulation research.

[63]  M. Hennig,et al.  Platelets subvert T cell immunity against cancer via GARP-TGFβ axis , 2017, Science Immunology.

[64]  R. Storey,et al.  Effect of P2Y12 inhibitors on inflammation and immunity , 2015, Thrombosis and Haemostasis.

[65]  G. Rewcastle,et al.  Identification of a Unique Co-operative Phosphoinositide 3-Kinase Signaling Mechanism Regulating Integrin αIIbβ3 Adhesive Function in Platelets* , 2007, Journal of Biological Chemistry.

[66]  C. Gachet,et al.  Purinergic Receptors in Thrombosis and Inflammation , 2015, Arteriosclerosis, thrombosis, and vascular biology.

[67]  R. Wetzker,et al.  Continuous signaling via PI3K isoforms beta and gamma is required for platelet ADP receptor function in dynamic thrombus stabilization. , 2006, Blood.

[68]  F. Di Virgilio,et al.  Increased Level of Extracellular ATP at Tumor Sites: In Vivo Imaging with Plasma Membrane Luciferase , 2008, PloS one.

[69]  A. Pandey,et al.  P2Y12 receptor inhibition augments cytotoxic effects of cisplatin in breast cancer , 2013, Medical Oncology.

[70]  P. Tchounwou,et al.  Cisplatin in cancer therapy: molecular mechanisms of action. , 2014, European journal of pharmacology.

[71]  G. Rewcastle,et al.  Identification of a unique co-operative phosphoinositide 3-kinase signaling mechanism regulating integrin alpha IIb beta 3 adhesive function in platelets. , 2007, The Journal of biological chemistry.

[72]  Yanhua Wang,et al.  Platelet P2Y12 Is Involved in Murine Pulmonary Metastasis , 2013, PloS one.

[73]  K. Huber,et al.  Pharmacokinetic basis of the antiplatelet action of prasugrel , 2012, Fundamental & clinical pharmacology.

[74]  R. Czajkowski,et al.  ADP‐evoked phospholipase C stimulation and adenylyl cyclase inhibition in glioma C6 cells occur through two distinct nucleotide receptors, P2Y1 and P2Y12 , 2002, FEBS letters.

[75]  S. Rangaraju,et al.  Activation of microglial P2Y12 receptor is required for outward potassium currents in response to neuronal injury , 2016, Neuroscience.